Novo Nordisk’s Summer of Reckoning: Prescription Dominance Meets Pipeline Verdict
Novo Nordisk’s oral Wegovy prescriptions outpace Eli Lilly’s Foundayo 2.4x, yet shares are down 45% from highs. Upcoming…
Novo Nordisk’s AI Search Dominance Faces a Pricing Reality Check
Novo Nordisk’s Wegovy captures 19% of AI chatbot mentions for weight-loss, but adjusted Q1 revenue dropped 4% and…
Novo Nordisk’s Billion-Dollar Buyback Meets a Pricing Squeeze and Digital Dominance in Obesity Marke
Novo Nordisk repurchases billions in B-shares amid 44% stock drop, buoyed by strong Wegovy sales and a digital…
New Status Quo: Germany Reaches for European Conventional Military Dominance
Trump sets his sights on crisis-hit Cuba after Iran action Following escalating tensions and military action involving Iran,…